Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome

Kaplan, Emma; Offermann, Elizabeth A.; Sievers, Jacqueline W.; Comi, Anne M.

doi:10.1016/j.pediatrneurol.2017.02.009

Cited by 72 publications

(78 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the remaining 8 clinical trials of various study design, 7 studies reported CBD positively (average dosing 23 mg/kg/d) and 1 study was neutral (8 mg/kg/d) . Within the 12 case studies and case series, 9 described positive effects of CBD (average dosing 16 mg/kg/d), 2 were neutral (average dosing 21 mg/kg/d) and 1 study described mixed results (3 mg/kg/d)…”

Section: Resultsmentioning

confidence: 99%

“…Within the other 3 clinical trials of prospective open‐label design ( n = 203), CBD was administered at an average dosing of 42 mg/kg/d and significant improvements in quality of life and seizure frequency compared to baseline were observed . 3 case series and 1 case report (total n = 16) reported beneficial effects of CBD on seizure frequency, duration and severity with an average administered dose of 21 mg/kg/d …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of cannabidiol dosing in clinical populations

Millar

Stone

Bellman

et al. 2019

Brit J Clinical Pharma

177

148

View full text Add to dashboard Cite

Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in a wide‐variety of contexts; however, its effective dose in different disease states remains unclear. This review aimed to investigate what doses have been applied in clinical populations, in order to understand the active range of CBD in a variety of medical contexts. Methods Publications involving administration of CBD alone were collected by searching PubMed, EMBASE and ClinicalTrials.gov . Results A total of 1038 articles were retrieved, of which 35 studies met inclusion criteria covering 13 medical contexts. Twenty‐three studies reported a significant improvement in primary outcomes (e.g. psychotic symptoms, anxiety, seizures), with doses ranging between <1 and 50 mg/kg/d. Plasma concentrations were not provided in any publication. CBD was reported as well tolerated and epilepsy was the most frequently studied medical condition, with all 11 studies demonstrating positive effects of CBD on reducing seizure frequency or severity (average 15 mg/kg/d within randomised controlled trials). There was no signal of positive activity of CBD in small randomised controlled trials (range n = 6–62) assessing diabetes, Crohn's disease, ocular hypertension, fatty liver disease or chronic pain. However, low doses (average 2.4 mg/kg/d) were used in these studies. Conclusion This review highlights that CBD has a potential wide range of activity in several pathologies. Pharmacokinetic studies as well as conclusive phase III trials to elucidate effective plasma concentrations within medical contexts are severely lacking and highly encouraged.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

A systematic review of cannabidiol dosing in clinical populations

Millar

Stone

Bellman

et al. 2019

Brit J Clinical Pharma

177

148

View full text Add to dashboard Cite

show abstract

“…32 Patients were randomized to either 10 mg/kg or 20 mg/kg of CBD versus placebo. 32 Patients were randomized to either 10 mg/kg or 20 mg/kg of CBD versus placebo.…”

Section: Class 1 Clinical Trialsmentioning

confidence: 99%

“…32 The patients were followed for about 14 weeks. For example, only 5 patients were included in a Sturge-Weber study.…”

Section: Class 1 Clinical Trialsmentioning

confidence: 99%

Cannabinoids for epilepsy: What do we know and where do we go?

Brodie¹,

Ben‐Menachem²

2017

Epilepsia

View full text Add to dashboard Cite

Over the past decade there has been an increasing interest in using cannabinoids to treat a range of epilepsy syndromes following reports of some remarkable responses in individual patients. The situation is complicated by the fact that these agents do not appear to work via their attachment to endogenous cannabinoid receptors. Their pharmacokinetics are complex, and bioavailability is variable, resulting in difficulty in developing a suitable formulation for oral delivery. Drug interactions also represent another complication in their everyday use. Nevertheless, recent randomized, placebo-controlled trials with cannabidiol support its efficacy in Dravet and Lennox-Gastaut syndromes. Further placebo-controlled studies are underway in adults with focal epilepsy using cannabidivarin. The many unanswered questions in the use of cannabinoids to treat epileptic seizures are briefly summarized in the conclusion.

show abstract

“…Así, el Sativex ® ha sido aprobado para el tratamiento del dolor central neuropático en la esclerosis múltiple y el dolor canceroso intratable (Russo et al, 2016); 2) reducción de síntomas positivos y severidad de los síntomas en la esquizofrenia , Zuardi et al, 2012; 3) utilidad en modelos animales (Huizenga et al, 2017, Kaplan et al, 2017b y clínicos (Devinsky et al, 2017, Kaplan et al, 2017a de epilepsia; 4) tratamiento de algunos trastornos de ansiedad, particularmente el trastorno por estrés postraumático (Walsh et al, 2017). De hecho, los autores postulan que el consumo de cannabis podría actuar, más que como una puerta de entrada para el consumo de otras drogas, como una puerta de salida de las mismas; 5) el CBD podría atenuar el refuerzo positivo que ejercerían los opioides al interferir en los mecanismos cerebrales responsables de las propiedades reforzadoras agudas de los opioides, pero no de la cocaína (Hurd, 2017); y 6) el consumo crónico de bajas dosis de 9-THC revertía el declive cognitivo en ratones "maduros o ancianos", y lo hacía por un mecanismo glutamatérgico mediado por el receptor CB 1 y la acetilación de histonas (Bilkei-Gorzo et al, 2017).…”

unclassified

Posmodernidad, sociedades adictivas, cannabis y comportamiento suicida: ¿Hacia un mundo feliz?

Blasco-Fontecilla

2018

Adicciones

View full text Add to dashboard Cite

«¿No es la felicidad más que la libertad de seguir los dictados de su propia voluntad o de sus deseos?».Crítica de la modernidad, Alain Touraine «El momento posmoderno es mucho más que una moda; explicita el proceso de indiferencia pura en el que todos los gustos, todos los comportamientos pueden cohabitar sin excluirse, todo puede escogerse a placer, lo más operativo como lo más esotérico, lo viejo como lo nuevo, la vida simple-ecologista como la vida hipersofisticada, en un tiempo desvitalizado sin referencia estable, sin coordenada mayor». La era del vacío, Giles Lipovetsky

show abstract

Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome

Cited by 72 publications

References 15 publications

A systematic review of cannabidiol dosing in clinical populations

A systematic review of cannabidiol dosing in clinical populations

Cannabinoids for epilepsy: What do we know and where do we go?

Posmodernidad, sociedades adictivas, cannabis y comportamiento suicida: ¿Hacia un mundo feliz?

Contact Info

Product

Resources

About